Trial Profile
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Idiopathic Short Stature: A Controlled, Prospective, Randomized, Multicenter Phase-II Study With An Untreated Control Group.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 01 Nov 2022 Primary endpoint has been met (Change in Height Standard Deviation Score for Chronological Age (delta HtSDSCA) from Baseline to 52 weeks) , according to Results published in the European Journal of Endocrinology
- 01 Nov 2022 Results published in the European Journal of Endocrinology
- 31 Oct 2022 Status changed from recruiting to completed.